Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert M Sharkey

Showing results (61-70 of 111) with videos related to

Pageof 12
Sort By:
Oncotarget|November 16, 2020
Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancerThomas M Cardillo, Diane L Rossi, Maria B Zalath, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 2, 2009
Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabineHabibe Karacay, Robert M Sharkey, David V Gold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methodsRobert M Sharkey, Habibe Karacay, Thomas M Cardillo, et al.
Cancer Research|June 19, 2008
A novel bispecific, trivalent antibody construct for targeting pancreatic carcinomaDavid V Gold, David M Goldenberg, Habibe Karacay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2015
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)Robert M Sharkey, William J McBride, Thomas M Cardillo, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 20, 2011
Optimized labeling of NOTA-conjugated octreotide with F-18Peter Laverman, Christopher A D'Souza, Annemarie Eek, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 17, 2014
Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled PeptideCatharina M van Rij, Cathelijne Frielink, David M Goldenberg, et al.
Clinical Colorectal Cancer|November 28, 2002
Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancerGeorge Hajjar, Robert M Sharkey, Jack Burton, et al.
Bioconjugate Chemistry|April 28, 2015
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other CancersThomas M Cardillo, Serengulam V Govindan, Robert M Sharkey, et al.
Molecular Cancer Therapeutics|December 14, 2002
Molecular advances in pretargeting radioimunotherapy with bispecific antibodiesChien-Hsing Chang, Robert M Sharkey, Edmund A Rossi, et al.
Pageof 12

Showing results (61-70 of 111) with videos related to

Sort By:
Pageof 12
Oncotarget|November 16, 2020
Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancerThomas M Cardillo, Diane L Rossi, Maria B Zalath, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 2, 2009
Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabineHabibe Karacay, Robert M Sharkey, David V Gold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methodsRobert M Sharkey, Habibe Karacay, Thomas M Cardillo, et al.
Cancer Research|June 19, 2008
A novel bispecific, trivalent antibody construct for targeting pancreatic carcinomaDavid V Gold, David M Goldenberg, Habibe Karacay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2015
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)Robert M Sharkey, William J McBride, Thomas M Cardillo, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 20, 2011
Optimized labeling of NOTA-conjugated octreotide with F-18Peter Laverman, Christopher A D'Souza, Annemarie Eek, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 17, 2014
Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled PeptideCatharina M van Rij, Cathelijne Frielink, David M Goldenberg, et al.
Clinical Colorectal Cancer|November 28, 2002
Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancerGeorge Hajjar, Robert M Sharkey, Jack Burton, et al.
Bioconjugate Chemistry|April 28, 2015
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other CancersThomas M Cardillo, Serengulam V Govindan, Robert M Sharkey, et al.
Molecular Cancer Therapeutics|December 14, 2002
Molecular advances in pretargeting radioimunotherapy with bispecific antibodiesChien-Hsing Chang, Robert M Sharkey, Edmund A Rossi, et al.
Pageof 12